XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation
Published on 08/07/2025 at 18:03 | prnewswire.co.uk
or press@xyra.us
Photo - https://mma.prnewswire.com/media/2346660/Xyra.jpg
Logo - https://mma.prnewswire.com/media/2346659/Xyra_Logo.jpg

en | boerse | 67995182 |
